申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US04616014A1
公开(公告)日:1986-10-07
New triazine derivatives represented by the formula: ##STR1## wherein R.sup.1 is aryl, pyridyl, thienyl, 1,2,3,4-tetrahydroquinolyl or 1,3,4,5-tetrahydro-2H-1-benzazepinyl, optionally substituted with lower alkyl, lower alkoxy, halogen, nitro or oxo, R.sup.2 is hydrogen, lower alkyl or carbamoyl substituted with lower alkyl or ar(lower)alkyl, and Z is a group selected from ##STR2## and pharmaceutically acceptable salt thereof, processes for preparation thereof and pharmaceutical compositions comprising the same of antihypertensive and antithrombotic activity.
新的三嗪衍生物由以下式子表示:##STR1## 其中R.sup.1是芳基,吡啶基,噻吩基,1,2,3,4-四氢喹啉基或1,3,4,5-四氢-2H-1-苯并氮杂环基,可选地被低烷基,低烷氧基,卤素,硝基或氧代基取代,R.sup.2是氢,低烷基或被低烷基或ar(较低)烷基取代的氨基甲酰基,Z是从以下组中选择的:##STR2## 以及其药学可接受的盐,其制备过程和包含具有抗高血压和抗血栓活性的药物组合物。